Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 12Neoplasms 4Neoplasm Metastasis 2Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 2Venous Thromboembolism 1Thoracic Neoplasms 1Solid Tumor 1Sexual Dysfunction, Physiological 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Noonan Syndrome 1Non-small Cell Lung Cancer Metastatic 1Non Small Lung Cancer 1Neoplasms by Site 1Mesothelioma 1Lung Diseases 1KRAS p, G12c Mutated /Advanced Metastatic NSCLC 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Erectile Dysfunction 1Carcinoma 1Bronchial Neoplasms 1Adenocarcinoma of Lung 1

Interventions

sotorasib 22'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation × sotorasib × Thoracic × Clear all
NCT05815173 2025-12-30

Ladarixin With Sotorasib in Advanced NSCLC

NYU Langone Health

Phase 1 Recruiting
40 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NYU Langone Health

Phase 2 Withdrawn
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡